title: Decreased expression of the mitochondrial metabolic enzyme  aconitase (ACO2) is associated with poor prognosis in gastric  cancer.
abstract: Alterations in energy metabolism play a major role in cancer development. Aconitase (ACO2) is an essential enzyme located in the mitochondria and catalyzes the interconversion of citrate and isocitrate in the tricarboxylic acid cycle. Recent studies suggest that the expression of ACO2 may be altered in certain types of cancer. The purpose of this study was to examine ACO2 expression in clinical tumor specimens from patients with gastric cancer and to evaluate the clinical relevance of ACO2 expression in gastric cancer. A total of 456 paraffin-embedded gastric cancer tissues and 30 pairs of freshly frozen tissues were used in this study. Real-time quantitative reverse transcription polymerase chain reaction, western blotting, and immunohistochemical staining were performed to measure ACO2 expression in tumor tissues and matched adjacent non-tumorous tissues. The results showed that the expression of ACO2 was significantly down-regulated in gastric cancer tissues compared with matched adjacent nontumorous tissues and was associated with clinical stage (p = 0.001), T classification (p = 0.027), N classification (p = 0.012), M classification (p = 0.002), and pathological differentiation states (p = 0.036). Patients with lower ACO2 expression had a shorter survival time than those with higher ACO2 expression. Univariate and multivariate analyses indicated that ACO2 expression functions as an independent prognostic factor (p < 0.001). Our data suggested that ACO2 could play an important role in gastric cancer and may potentially serve as a prognostic biomarker.
authors.affiliation: State Key Laboratory of Oncology in Southern China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
authors.forename: Peng
authors.initials: P
authors.lastname: Wang
authors.forename: Cong
authors.initials: C
authors.lastname: Mai
authors.forename: Yong-li
authors.initials: YL
authors.lastname: Wei
authors.forename: Jing-jing
authors.initials: JJ
authors.lastname: Zhao
authors.forename: Yu-min
authors.initials: YM
authors.lastname: Hu
authors.forename: Zhao-lei
authors.initials: ZL
authors.lastname: Zeng
authors.forename: Jing
authors.initials: J
authors.lastname: Yang
authors.forename: Wen-hua
authors.initials: WH
authors.lastname: Lu
authors.forename: Rui-hua
authors.initials: RH
authors.lastname: Xu
authors.forename: Peng
authors.initials: P
authors.lastname: Huang
mesh_terms: D000154:Aconitate Hydratase / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000235:genetics; D000368:Aged; D014408:Biomarkers, Tumor / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000235:genetics; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008875:Middle Aged; D024101:Mitochondrial Proteins / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000235:genetics; D011379:Prognosis; D012333:RNA, Messenger / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics; D013274:Stomach Neoplasms / Q000175:diagnosis* / Q000201:enzymology* / Q000235:genetics; D015996:Survival Rate / Q000639:trends
chemical_list: D014408:Biomarkers, Tumor; D024101:Mitochondrial Proteins; D012333:RNA, Messenger; C476079:ACO2 protein, human; D000154:Aconitate Hydratase
references.citation: Annu Rev Cell Dev Biol. 2011;27:441-64
references.pmid: 21985671
references.citation: Nat Cell Biol. 2002 Sep;4(9):674-80
references.pmid: 12198491
references.citation: Trends Biochem Sci. 1997 Jan;22(1):3-6
references.pmid: 9020582
references.citation: Proc Natl Acad Sci U S A. 1989 May;86(10):3639-43
references.pmid: 2726740
references.citation: Biometals. 2007 Jun;20(3-4):549-64
references.pmid: 17205209
references.citation: J Med Genet. 2003 May;40(5):e73
references.pmid: 12746427
references.citation: Cancer Res. 1991 Feb 1;51(3):794-8
references.pmid: 1846317
references.citation: Cell. 2011 Mar 4;144(5):646-74
references.pmid: 21376230
references.citation: FASEB J. 1993 Dec;7(15):1442-9
references.pmid: 8262329
references.citation: Lancet. 2005 Nov 19;366(9499):1784-93
references.pmid: 16298215
references.citation: World J Gastrointest Oncol. 2012 Jul 15;4(7):156-69
references.pmid: 22844547
references.citation: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references.pmid: 22237781
references.citation: Clin Cancer Res. 2007 Jul 15;13(14):4154-63
references.pmid: 17634543
references.citation: Gastric Cancer. 2005;8(2):86-94
references.pmid: 15864715
references.citation: Mol Cell Proteomics. 2006 Jun;5(6):1119-30
references.pmid: 16554294
references.citation: Curr Opin Genet Dev. 2008 Feb;18(1):54-61
references.pmid: 18387799
references.citation: Science. 2005 Feb 4;307(5710):714-7
references.pmid: 15692048
references.citation: Neoplasia. 2008 Aug;10(8):745-56
references.pmid: 18670636
references.citation: Mol Cell Biol. 2009 Aug;29(15):4080-90
references.pmid: 19470762
references.citation: Mol Cell Proteomics. 2010 Dec;9(12):2617-28
references.pmid: 20699381
references.citation: Cancer Res. 2002 Jan 1;62(1):233-40
references.pmid: 11782383
references.citation: Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7536-40
references.pmid: 1502165
references.citation: Trends Biochem Sci. 2005 Jun;30(6):294-6
references.pmid: 15950872
references.citation: FEBS Lett. 1995 Jan 16;358(1):1-3
references.pmid: 7821417
references.citation: Science. 1956 Aug 10;124(3215):269-70
references.pmid: 13351639
references.citation: Cancer Cell. 2008 Jun;13(6):472-82
references.pmid: 18538731
references.citation: Semin Cancer Biol. 2009 Feb;19(1):12-6
references.pmid: 19114105
references.citation: J Clin Oncol. 2005 Oct 10;23(29):7286-95
references.pmid: 16145069
references.citation: Proc Natl Acad Sci U S A. 2007 Aug 21;104(34):13738-43
references.pmid: 17698960
references.citation: Science. 1956 Feb 24;123(3191):309-14
references.pmid: 13298683